Although HIV treatment reduces the risk of transmission during breastfeeding, this risk is not zero. Latest results presented at AIDS 2018 reported that 2/8 cases when transmission occurred form breastfeeding were in women whose most recent viral load was <40 copies/mL.

A dual antiretroviral regimen containing dolutegravir and boosted darunavir maintains viral suppression in most people who switch from a suppressive three-drug regimen.

There is a high prevalence of hypertension among HIV-positive people starting ART in SA.

Early antiretroviral therapy (ART) reduces the risk of liver fibrosis progression in people living with HIV, including in people who do not have co-infection with viral hepatitis, according to the results of the SMART study.

Research presented at the HIV Drug Therapy Conference in Glasgow shows that pre-exposure prophylaxis (PrEP) could be given to millions of people worldwide with no increased risk of safety issues during treatment.